Observational analysis
Study theme · illustration
Read the results alongside the study design, safety findings and limitations.

Who was studied?

Retrospective cohort of 36 selected patients aged 75–93; 34 were response-evaluable, while all 36 contributed to survival and safety analyses.

What does the publication report?

ORR was 23.5% (8/34) and DCR 70.6% (24/34) in response-evaluable patients. In all 36 patients, median PFS was 7.0 months and median OS 11.1 months.

Safety findings

TRAEs occurred in 34/36 patients (94.4%); three (8.3%) had grade ≥3 events. No grade 5 events were observed.

How should we interpret it?

Small retrospective cohort with selection bias. It is distinct from the prospective PRaG 9.0 protocol.

Read the original source

This independently written summary was checked against the original full publication. It is an educational summary, not a full-paper translation or clinical recommendation.

Safety and efficacy of PRaG therapy in elderly cancer patients · DOI: 10.1093/immadv/ltag019 · PMID: 42694766

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.